On Wednesday, Rovi Corporation (NASDAQ:ROVI)’s shares declined 4.52% to $10.15.
Rovi Corporation (ROVI) declared the appointment of Eddy Hartenstein to its Board of Directors, effective as of September 18, 2015, expanding the size of the board from seven to eight directors.
Jim Meyer, Chairman of the Board and Chairman of Rovi’s Corporate Governance and Nominating Committee, said, “Starting last year, Rovi’s Board decided to augment the Board with key expertise in core planned areas. The Board retained an independent professional search firm, Howard Fischer Associates, to identify qualified new Board candidates with high caliber experience and demonstrated success in (1) advanced data and analytics, and (2) the service provider space. With more than three decades of experience in the media and service provider industries, Eddy is a true industry veteran and brings noteworthy industry relationships in addition to senior leadership, technological and industry expertise to Rovi’s Board. We also believe the Company benefits from Eddy’s deep experience in the multi-channel distribution of media content, in addition to his previous operational experience, counting serving as the chief executive officer, of large, complex, publicly-held companies. In sum, we are very happy to have such an extremely qualified business leader add to the strength of Rovi’s Board of Directors.”
Rovi Corporation provides integrated solutions for the discovery and personalization of digital entertainment to service providers and consumer electronics (CE) industry worldwide.\
Clovis Oncology Inc (NASDAQ:CLVS)’s shares dropped -0.52% to $99.72.
Clovis Oncology (CLVS) declared that three oral presentations and four scientific posters highlighting updated results from clinical studies of the company’s two compounds in advanced clinical development are being presented at the 2015 European Cancer Congress (ECC), which will take place Sept. 25-29 in Vienna, Austria.
“We are happy to have the opportunity to share noteworthy clinical progress across our product pipeline at ECC this year,” said Patrick J. Mahaffy, CEO and President of Clovis Oncology. “Some key highlights comprise updated results from our rucaparib studies in the treatment of advanced ovarian cancer, counting ARIEL2, for which we intend to file our initial regulatory submissions in the US in mid-2016.”
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which comprise Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers.
At the end of Wednesday’s trade, Constellium NV (NYSE:CSTM)‘s shares dipped -2.98% to $XXX.
Constellium N.V. (CSTM) declared it will provide a live webcast of its Analyst Field Trip Conference being held on October 1st, 2015 at 8:00am Central Time in Muscle Shoals, Alabama.
Chaired by Constellium’s Pierre Vareille, Chief Executive Officer, and Didier Fontaine, Chief Finance Officer, the conference will cover the following topics:
- Welcome Address – Paul Blalock, Head of Investor Relations, U.S.
- Automotive Market Perspectives and Constellium’s Offerings – Peter Basten, Vice President Strategy and Business Development
- Increasing Constellium’s Body-in-White Production Capacity (U.S./Europe) – Simon Laddychuk, Vice President and Chief Technical Officer
- Plant Presentation – Wes Oberholzer, Vice President Packaging and Automotive Rolled Products North America
Constellium N.V. engages in the design, manufacture, and sale of specialty rolled and extruded aluminum products for the aerospace, packaging, and automotive end-markets. The company operates in three segments: Aerospace & Transportation, Packaging & Automotive Rolled Products, and Automotive Structures & Industry.
T. Rowe Price Group Inc (NASDAQ:TROW), ended its Wednesday’s trading session with -0.28% loss, and closed at $68.87.
T. Rowe Price Group, Inc. (TROW) declared that its board of directors has elected H. Lawrence “Larry” Culp, Jr. and Alan D. Wilson to be independent directors of the company.
Mr. Culp was chief executive officer and president of Danaher Corporation from 2001 to 2014 and is now a senior advisor to the company. He serves as chair of the Board of Visitors and Governors for Washington College and as a member of the Board of Trustees of Wake Forest University. Mr. Culp recently joined the faculty of the Harvard Business School as a senior lecturer and in 2014 he ranked 38th on Harvard Business Review’s list of the 100 best-performing CEOs in the world.
Mr. Culp holds a Bachelor of Arts degree from Washington College and an M.B.A from Harvard Business School.
Mr. Wilson is chairman and chief executive officer of McCormick & Company, Incorporated, a position he has held since 2008. He serves on the boards of directors of WestRock Company, the Grocery Manufacturers Association, the National Association of Manufacturers, and the Greater Baltimore Committee. Mr. Wilson also serves on the Board of Visitors of the University of Maryland, Baltimore County (UMBC) in addition to the Advisory Council for the University of Tennessee’s Haslam College of Business. He was named the 2013 Business Leader of the Year by Loyola University Maryland’s Sellinger School of Business and Administration.
T. Rowe Price Group, Inc. is a publicly owned asset administration holding company. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. Through its auxiliaries, it launches and manages equity and fixed income mutual funds. The firm also launches balanced mutual funds and private equity funds.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
